CNTO-530

CNTO-530
[[File:|frameless|220px|alt=|]]
INN
Drug class
Routes of administration
Pregnancy category
Bioavailability
Metabolism
Elimination half-life
Excretion
Legal status
CAS Number
PubChem
DrugBank
ChemSpider
KEGG

CNTO-530 is a biopharmaceutical agent developed for the treatment of anemia, particularly in patients with chronic kidney disease (CKD). It is a type of erythropoiesis-stimulating agent (ESA) designed to stimulate the production of red blood cells by mimicking the action of erythropoietin, a hormone naturally produced by the kidneys.

Mechanism of Action

CNTO-530 functions by binding to and activating the erythropoietin receptor on the surface of erythroid progenitor cells in the bone marrow. This activation leads to the proliferation and differentiation of these progenitor cells into mature red blood cells, thereby increasing the red blood cell count and improving oxygen delivery to tissues.

Development and Clinical Trials

CNTO-530 was developed by Janssen Biotech, a subsidiary of Johnson & Johnson. It underwent several phases of clinical trials to evaluate its safety, efficacy, and optimal dosing regimens. The trials primarily focused on patients with anemia due to chronic kidney disease, a condition where the kidneys fail to produce adequate amounts of erythropoietin.

Potential Benefits

The use of CNTO-530 in treating anemia associated with CKD offers several potential benefits:

• Reduced Need for Blood Transfusions: By stimulating endogenous red blood cell production, CNTO-530 can reduce the need for blood transfusions, which carry risks such as iron overload and transfusion reactions.
• Improved Quality of Life: Anemia can cause symptoms such as fatigue, weakness, and shortness of breath. By alleviating these symptoms, CNTO-530 can improve the quality of life for patients.

Safety and Side Effects

As with other erythropoiesis-stimulating agents, CNTO-530 may have side effects, including:

• Hypertension: Increased blood pressure is a common side effect due to the increased red blood cell mass.
• Thromboembolic Events: There is a risk of blood clots, which can lead to serious complications such as stroke or myocardial infarction.

Regulatory Status

As of the latest updates, CNTO-530 has not been approved for general clinical use and remains under investigation. The regulatory status may vary by region and is subject to change based on ongoing research and clinical trial outcomes.

Also see

• Erythropoietin
• Anemia of chronic disease
• Chronic kidney disease
• Erythropoiesis-stimulating agent